GlassScriptPhysician profile
Carmen M Klass
NPI 1598871410
$12,573.79
in general payments reported to CMS, 2019-2025
40 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,339 · 2020: $495 · 2021: $472 · 2022: $542 · 2023: $2,679 · 2024: $933 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,220 · Food and Beverage: $2,160 · Education: $336 · Travel and Lodging: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,220.00 |
| Food and Beverage | $2,159.85 |
| Education | $335.83 |
| Travel and Lodging | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $5,551.91 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $2,354.37 | 2023-2025 | Calquence, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $527.41 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $521.64 | 2019-2021 | |
| Pfizer INC. | $506.43 | 2019-2025 | |
| Janssen Biotech, INC. | $414.39 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Gilead Sciences, INC. | $325.49 | 2021-2025 | Trodelvy |
| Abbvie INC. | $279.07 | 2024-2025 | |
| Seagen INC. | $268.58 | 2020-2023 | Tukysa, Adcetris |
| Daiichi Sankyo INC. | $257.08 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Merck Sharp & Dohme LLC | $250.15 | 2019-2023 | Lynparza, Keytruda |
| Celgene Corporation | $185.25 | 2019-2025 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $184.77 | 2019-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $136.93 | 2021-2025 | Ojjaara, Jemperli |
| Eisai INC. | $92.45 | 2019-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Klass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.